Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Dec;74(24):11574-80.
doi: 10.1128/jvi.74.24.11574-11580.2000.

Functional mapping of protective domains and epitopes in the rotavirus VP6 protein

Affiliations

Functional mapping of protective domains and epitopes in the rotavirus VP6 protein

A H Choi et al. J Virol. 2000 Dec.

Abstract

The purpose of this study was to determine which regions of the VP6 protein of the murine rotavirus strain EDIM are able to elicit protection against rotavirus shedding in the adult mouse model following intranasal (i.n.) immunization with fragments of VP6 and a subsequent oral EDIM challenge. In the initial experiment, the first (fragment AB), middle (BC), or last (CD) part of VP6 that was genetically fused to maltose-binding protein (MBP) and expressed in Escherichia coli was examined. Mice (BALB/c) immunized with two 9-microg doses of each of the chimeras and 10 microg of the mucosal adjuvant LT(R192G) were found to be protected against EDIM shedding (80, 92, and nearly 100% reduction, respectively; P </= 0.01) following challenge. Because CD produced almost complete protection, we prepared four E. coli-expressed, MBP-fused chimeras containing overlapping fragments of the CD region (i.e., CD1, CD2, CD3, and CD4) whose lengths ranged from 61 to 67 amino acid residues. Following i.n. immunization, CD1, CD2, and CD4 induced significant (P </= 0.004) protection (88, 84, and 92% reduction, respectively). In addition, 11 peptides (18 to 30 residues) of the CD region with between 0 and 13 overlapping amino acids were synthesized. Two 50-microg doses of each peptide with LT(R192G) were administered i.n. to BALB/c mice. Five peptides were found to elicit significant (P </= 0.02) protection. Moreover, a 14-amino-acid region within peptide 6 containing a putative CD4(+) T-cell epitope was found to confer nearly complete protection, suggesting a protective role for CD4(+) T cells. Mice that were protected by fragments BC and CD1 and four of the five protective synthetic peptides did not develop measurable rotavirus antibodies in serum or stool, implying that protection induced by these domains was not dependent on antibody. Together, these observations suggest that multiple regions of VP6 can stimulate protection, a region of VP6 as small as 14 amino acids containing a CD4(+) T-cell epitope can stimulate nearly complete protection, and protection mediated by a subset of epitopes in the VP6 protein does not require antibodies in BALB/c mice.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Schematic summary of the AB, BC, and CD fragments of VP6 and synthetic peptides (1 through 11 and 6-14) used to map protective domains and epitopes in VP6 and in its CD region. The numbers in front of and following the bars indicate the locations of the regions in the primary sequence of VP6. The protective efficacies of VP6 and the two groups of VP6 fragments (i.e., AB, BC, and CD and CD1, CD2, CD3, and CD4) and synthetic peptides are indicated as percent reduction in rotavirus shedding relative to mock-immunized mice. a Average percent reduction in shedding (range) of three experiments.

References

    1. Ausubel F M, Brent R, Kingston R E, Moore D D, Seidman J G, Smit J A, Struhl K, editors. Current protocols in molecular biology. New York, N.Y: Greene Publishing Associates, Inc., and John Wiley & Sons, Inc.; 1995.
    1. Banos D M, Lopez S, Arias C F, Esquivel F R. Identification of a T-helper cell epitope on the rotavirus VP6 protein. J Virol. 1997;71:419–426. - PMC - PubMed
    1. Bern C, Martines J, de Zoysa I, Glass R I. The magnitude of the global problem of diarrhoeal disease: a ten-year update. Bull W H O. 1992;70:705–714. - PMC - PubMed
    1. Bernstein D I, Smith V E, Sander D S, Pax K A, Schiff G M, Ward R L. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis. 1990;162:1055–1062. - PubMed
    1. Bernstein D I, Glass R I, Rodgers G, Davidson B L, Sack D A. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. JAMA. 1995;273:1191–1196. - PubMed

Publication types